Job title: Senior Director of Antibody Validation & Characterization
Will Howat leads Abcam’s global Imaging and Immunohistochemistry team as Director of Antibody Validation & Characterization. Prior to joining Abcam in 2018, he worked at AstraZeneca as Team Leader of its Molecular Pathology Group, where his team developed biomarker assays for preclinical, Phase 1 and Phase 2 clinical trials. Before that he was at the Cancer Research UK’s Cambridge Institute, where he set up and ran the Histopathology/ISH core facility for nine years. He has also worked at the Wellcome Sanger Institute on the Atlas of Protein Expression and was responsible for R&D in within the Immunohistochemistry group.
Will has a BSc (Hons) in Immunology & Pharmacology from the University of Strathclyde and a PhD in Pathology from the University of Southampton. His publications span key journals such as The Lancet, Nature, Science, Nature Genetics, American Journal of Pathology, and the Journal of Pathology.
Panel Discussion & Live Audience Q&A: Unlocking the Next Generation of Biomarker Discovery to Advance Clinical Assets: A Case Study with Pionyr Immunotherapeutics 6:35 pm
• Hear from Pionyr Immunotherapeutics on the challenges faced when trying to find a good quality reagent in the early development stages and how to overcome them • From pharma’s perspective, discover the importance of a strong partnership to enhance your development journey and move up through the clinical development chain • Discover how Abcam…Read more
day: From Discovery to Clinic: New Opportunities for Biomarker Success - Agenda
Panel + Q&A: Reaching New Heights by Working Together: How Abcam, Ultivue & Targos Builds Robust Partnership Chain & Support with Pharma from Clinical Trials Through to IVD 12:35 pm
How our commitment to the highest standards in immune-oncology, cancer and neuroscience diagnostics adds value to your work We understand your specific needs and our robust partnership process can help you rapidly advance the key stages of your mIHC from analytical validation to demonstration of clinical utility and all the way through to IVD application…Read more
day: Abcam Webinar Agenda
Presentation: The Value of Using mIHC for Clinical Trials Through to IVD Applications 12:05 pm
The potential and promise of mIHC for routine clinical application Challenges of getting your mIHC ready for IVD use and how to overcome them The value of the right content to fuel mIHC and the importance of reagent and panel validationRead more
day: Abcam Webinar Agenda